[go: up one dir, main page]

AR074874A1 - Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto. - Google Patents

Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.

Info

Publication number
AR074874A1
AR074874A1 ARP090105072A ARP090105072A AR074874A1 AR 074874 A1 AR074874 A1 AR 074874A1 AR P090105072 A ARP090105072 A AR P090105072A AR P090105072 A ARP090105072 A AR P090105072A AR 074874 A1 AR074874 A1 AR 074874A1
Authority
AR
Argentina
Prior art keywords
compound
treating
protected compound
amino
infections
Prior art date
Application number
ARP090105072A
Other languages
English (en)
Inventor
Richard A Leese
Original Assignee
Biosource Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosource Pharm Inc filed Critical Biosource Pharm Inc
Publication of AR074874A1 publication Critical patent/AR074874A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica caracterizada porque comprende un compuesto de la fórmula (1) o una sal aceptable para uso farmacéutico de la misma. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque además comprende un vehículo aceptable para uso farmacéutico, donde el compuesto antibacteriano es (S)-4-amino-N-((2S,3R)-1-((S)-4-amino-1-oxo-1-((3s,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoetil)-15-bencil-3-(( R)-1-hidroxietil)-12-isobutil-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazaciclotricosan-21-ilamino)butan-2-ilamino)-3-hidroxi-1-oxobutan-2-il)-2-(3-(2-clorofenil)ureido)butanamida. Reivindicación 13: Un proceso para preparar el compuesto antibacteriano caracterizado porque comprende: (a) tratar una polimixina B con un grupo de protección de amino que comprende al menos un sustituyente acídico para formar un compuesto protegido; (b) tratar el compuesto protegido con un agente desacilante, para formar al menos un compuesto protegido desacilado; (c) tratar el al menos un compuesto protegido desacilado con un isocianato para formar al menos un compuesto protegido acilado; y (d) tratar el al menos un compuesto protegido acilado con una base orgánica para formar el compuesto antibacteriano que tiene la fórmula (1). Reivindicación 14: El proceso de la reivindicación 13, caracterizado porque: (a) el agente desacilante es producido por Actinoplanes utahensis; y (b) el grupo de protección es 2-sulfo-9-fluorenilmetoxicarbonilo.
ARP090105072A 2008-12-23 2009-12-22 Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto. AR074874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14040808P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
AR074874A1 true AR074874A1 (es) 2011-02-16

Family

ID=42110218

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090105072A AR074874A1 (es) 2008-12-23 2009-12-22 Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.

Country Status (7)

Country Link
US (2) US8343912B2 (es)
AR (1) AR074874A1 (es)
CA (1) CA2747995A1 (es)
NZ (1) NZ593892A (es)
TW (1) TW201035111A (es)
WO (1) WO2010075416A1 (es)
ZA (1) ZA201105290B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
AU2012329098B2 (en) 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
MX355217B (es) * 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
EP2679236A1 (de) 2012-06-29 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Dosierungsanleitung für endotoxinbindende Lipopeptide
EP2999711B1 (en) 2013-05-22 2022-06-29 Spero Therapeutics, Inc. Polymyxin derivatives and their use in combination therapy together with different antibiotics
SI3116897T1 (sl) * 2014-03-11 2022-06-30 Spero Therapeutics, Inc. Derivati polimiksina in njihova uporaba v kombinacijskem zdravljenju skupaj z različnimi antibiotiki
EP3126376B1 (en) * 2014-04-01 2024-08-21 Monash University Polymyxin derivatives as antimicrobial compounds
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
TWI757229B (zh) 2014-11-26 2022-03-11 美商斯佩羅治療學股份有限公司 用於治療微生物感染的化合物以及該化合物的用途
JP6896628B2 (ja) 2014-12-16 2021-06-30 シャンハイ ミクウルク ファーマシューティカル シーオー．エルティーディー 細菌感染症の治療のための抗微生物性ポリミキシン
CN108350034B (zh) * 2015-09-29 2022-03-11 莫纳什大学 抗微生物的多黏菌素衍生的化合物
WO2017209719A1 (en) 2016-06-01 2017-12-07 Gazel Deniz Antimicrobial effect of methylene blue on colistin resistant acinetobacter baumannii bacteria
WO2017218922A2 (en) * 2016-06-17 2017-12-21 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
WO2018108154A1 (zh) * 2016-12-16 2018-06-21 中国医学科学院医药生物技术研究所 多粘菌素衍生物及其制备方法和应用
WO2018195078A1 (en) * 2017-04-18 2018-10-25 The Regents Of The University Of California Anti-microbial agent-polymer conjugates and methods of use thereof
US11459357B2 (en) 2018-06-25 2022-10-04 Spero Therapeutics, Inc. Polymyxin compounds
CN109206486B (zh) * 2018-09-03 2020-11-10 杭州中美华东制药有限公司 一种硫酸多黏菌素b的杂质及其制备方法
EP3636659A1 (en) * 2018-10-08 2020-04-15 Universitat de Barcelona Polymyxin-based compounds useful as antibacterial agents
CN115298198A (zh) 2020-01-21 2022-11-04 上海盟科药业股份有限公司 用于肾相关癌症靶向治疗的新型化合物和组合物
KR20250037611A (ko) * 2023-09-07 2025-03-18 웰펩 주식회사 그람 음성균 및 다제내성 그람 음성균에 우수한 항균 활성을 갖는 신규 폴리믹신 유사체, 이를 포함하는 항균용 조성물

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3753970A (en) * 1970-08-04 1973-08-21 Rhone Poulenc Sa Cyclopeptides derived from polymyxins and their preparation
FR2124060B1 (es) 1971-02-02 1974-04-12 Rhone Poulenc Sa
US4091092A (en) * 1976-09-20 1978-05-23 E. R. Squibb & Sons, Inc. Polymyxin F and process of producing polymyxin F
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
DE3376424D1 (en) * 1982-02-27 1988-06-01 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4524135A (en) * 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) * 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) * 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4399067A (en) * 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) * 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) * 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4895566A (en) 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
CA1332939C (en) 1986-08-07 1994-11-08 Henrich Hasko Paradies 2,5,6-substituted-n -alkylpyrimidines
US4830860A (en) 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
US5755788A (en) 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
US20010021697A1 (en) * 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
US5028590A (en) * 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
US5039789A (en) * 1988-04-11 1991-08-13 Eli Lilly And Company A54145 cyclic peptides
US5254535A (en) 1989-04-17 1993-10-19 The Children's Hospital Of Pennsylvania Composition and treatment with biologically active peptides and antibiotic
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5459237A (en) 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
JPH04167172A (ja) * 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5082653A (en) 1990-10-31 1992-01-21 Warner-Lambert Company Anti-plaque compositions comprising a combination of morpholinoamino alcohol and antibiotic
US5686065A (en) 1991-03-27 1997-11-11 Special Advanced Biomaterials, Inc. Topical siloxane sunscreen compositions having enhanced performance and safety
WO1992017195A1 (en) 1991-04-08 1992-10-15 Magainin Pharmaceuticals, Inc. Novel peptide compositions and uses therefor
CA2118939A1 (en) 1991-09-13 1993-04-01 W. Lee Maloy Biologically active amphiphilic peptide compositions and uses thereof
TW274552B (es) 1992-05-26 1996-04-21 Hoechst Ag
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5283005A (en) 1992-10-08 1994-02-01 Olin Corporation Synergistic biocide combination for industrial fluids
US5424290A (en) 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
US5360788A (en) 1992-11-10 1994-11-01 Olin Corporation Personal care composition containing pyrithione and a basic lipopeptide
US5370876A (en) 1993-01-08 1994-12-06 Microbarriers Antimicrobial protective skin composition and method for protecting skin from body fluids
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
CA2112776C (en) 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US20040023884A1 (en) 1993-03-12 2004-02-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5635216A (en) 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
WO1995005384A1 (en) 1993-08-13 1995-02-23 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
US5587358A (en) 1994-05-09 1996-12-24 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators of antimicrobial activity
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US20020150964A1 (en) 1995-12-19 2002-10-17 Centre National De La Recherche Scientifique Peptides for the activation of the immune system in humans and animals
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6767904B2 (en) 1998-03-06 2004-07-27 Bringham Young University Steroid derived antibiotics
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6468967B1 (en) 1998-09-25 2002-10-22 Cubist Pharmaceuticals, Incorporated Methods for administration of antibiotics
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US6515104B1 (en) 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6964948B2 (en) 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
CN1361791A (zh) 1999-07-15 2002-07-31 伊莱利利公司 脂缩肽脱酰方法
US6380356B1 (en) * 1999-12-07 2002-04-30 Advanced Medicine, Inc. Multivalent polymyxin antibiotics
JP4990456B2 (ja) 1999-12-15 2012-08-01 キュービスト ファーマシューティカルズ， インコーポレイテッド 抗菌剤としてのダプトマイシンアナログ
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
CN1423655A (zh) 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的新颖的脂肽
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
JP2003535165A (ja) 2000-05-30 2003-11-25 ビリディス バイオテック インコーポレイテッド ポリユビキチン系ヒドロゲルとその用途
MXPA03000041A (es) 2000-06-30 2003-10-15 Procter & Gamble Composiciones orales que comprenden agentes microbianos.
US6511962B1 (en) * 2000-07-17 2003-01-28 Micrologix Biotech Inc. Derivatives of laspartomycin and preparation and use thereof
AU2001278933B2 (en) 2000-07-17 2006-05-25 Migenix Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
EP1351992B1 (en) 2001-01-16 2011-03-02 Ramot at Tel Aviv University Ltd. Hybrid peptides for treatment of bacteremia and septicemia
OA12542A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
DE60237363D1 (de) 2001-03-15 2010-09-30 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
ATE430160T1 (de) 2001-08-06 2009-05-15 Cubist Pharm Inc Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
US6681765B2 (en) 2001-12-18 2004-01-27 Sheree H. Wen Antiviral and antibacterial respirator mask
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
EP1360961A1 (en) 2002-05-07 2003-11-12 AM-Pharma B.V. Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
US6767718B2 (en) 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
US7884083B2 (en) 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US20040037895A1 (en) 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
BRPI0410377A (pt) 2003-05-16 2006-06-13 Blue Membranes Gmbh implantes medicinais revestidos bio-compatìveis
AU2004277977B2 (en) * 2003-09-30 2010-10-28 Biomechanisms Inc. Compositions and methods for treating burns
JP2007513083A (ja) 2003-11-10 2007-05-24 アンジオテック インターナショナル アーゲー 医療用移植片および繊維誘発剤
US7364747B1 (en) 2004-02-02 2008-04-29 S.S. Steiner, Inc. Process and product for inhibiting or preventing bacterial infections
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
JP2008508243A (ja) 2004-07-30 2008-03-21 パルメド・ソシエテ・アノニム アミノキノリンをｑとし、抗生物質残基をａとする混成分子ｑａ、その合成及び抗菌剤としての使用
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20060195183A1 (en) 2005-02-18 2006-08-31 The Cleveland Clinic Foundation Apparatus and methods for replacing a cardiac valve
EP1893131A1 (en) 2005-04-20 2008-03-05 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
WO2007011799A1 (en) 2005-07-15 2007-01-25 The Cleveland Clinic Foundation Apparatus and method for remodeling a cardiac valve annulus
US20070197957A1 (en) 2005-10-03 2007-08-23 Hunter William L Implantable sensors, implantable pumps and anti-scarring drug combinations
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
US20070208134A1 (en) 2005-10-03 2007-09-06 Hunter William L Anti-scarring drug combinations and use thereof
US20070196421A1 (en) 2005-10-03 2007-08-23 Hunter William L Soft tissue implants and drug combination compositions, and use thereof
KR100750658B1 (ko) 2005-12-09 2007-08-20 한국생명공학연구원 폴리믹신 생합성 효소 및 이를 코딩하는 유전자 군
CA2632871A1 (en) 2006-01-30 2007-08-09 Angiotech Pharmaceuticals, Inc. Sutures and fibrosing agents
WO2007095187A2 (en) 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
US20070203080A1 (en) 2006-02-15 2007-08-30 The Regents Of The University Of California New Drug Delivery System for Crossing the Blood Brain Barrier
US20070197658A1 (en) 2006-02-22 2007-08-23 David Sunil A Polyamines and their use as antibacterial and sensitizing agents
US8585753B2 (en) 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
US20070243275A1 (en) 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US20090318403A1 (en) 2006-08-03 2009-12-24 Prosensa Technologies B.V. Antibiotic composition
SI2057185T1 (sl) 2006-08-11 2016-10-28 Northern Antibiotics Oy Derivati polimiksina in njihove uporabe
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
WO2008076806A2 (en) 2006-12-15 2008-06-26 Trustees Of Boston University Compositions and methods to potentiate colistin activity
WO2009009171A2 (en) 2007-04-02 2009-01-15 Sideromics, Llc Methods for preventing or treating infectious diseases using gallium compounds
US8066689B2 (en) 2007-07-11 2011-11-29 Apollo Endosurgery, Inc. Methods and systems for submucosal implantation of a device for diagnosis and treatment with a therapeutic agent
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
US20090214601A1 (en) 2007-09-28 2009-08-27 Chappa Ralph A Porous Drug Delivery Devices and Related Methods
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections

Also Published As

Publication number Publication date
US8343912B2 (en) 2013-01-01
ZA201105290B (en) 2012-03-28
WO2010075416A1 (en) 2010-07-01
CA2747995A1 (en) 2010-07-01
TW201035111A (en) 2010-10-01
NZ593892A (en) 2013-11-29
US20130345121A1 (en) 2013-12-26
US8937040B2 (en) 2015-01-20
US20100160215A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
AR074874A1 (es) Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
EP4516301A3 (en) Nitrile-containing compounds for use as medicaments
DOP2020000058A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
AR064420A1 (es) Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
BR112012021931A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
PH12012501881A1 (en) 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication
BRPI0922220B8 (pt) uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
TW200806299A (en) Treatment of pain
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
WO2014165107A3 (en) Mannose derivatives for treating bacterial infections
RU2015134149A (ru) Композиции и способы лечения бактериальных инфекций
EP2590978A4 (en) CARBAPENEM ANTIBACTERIA WITH GRAM NEGATIVE ACTIVITY
BRPI0607702A2 (pt) composto, composição farmacêutica, uso do referido composto, e método de preparação de um composto
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure